Search results for "Cross-reactivity"

showing 4 items of 14 documents

Hsp60 and AChR cross-reactivity in myasthenia gravis: An update.

2010

Settore BIO/16 - Anatomia UmanaChaperonin 60Biologymedicine.disease_causemedicine.diseaseCross-reactivityMyasthenia gravisNeurologyhsp60 myastenia gravisMyasthenia GravisImmunologymedicineHumansReceptors CholinergicHSP60Neurology (clinical)AutoantibodiesAcetylcholine receptor
researchProduct

Mapping routine measles vaccination in low- and middle-income countries

2021

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here we generated annual estimates of routine childhoo…

and promotion of well-beingVacunación MasivaInternationalityDisease preventionchildren under 5 years oldGeographic MappingRural Healthmedicine.disease_causeCross-reactivity0302 clinical medicineRA0421Vaccination Refusal030212 general & internal medicineChildimmunity patternsPediatric0303 health sciencesPublic healthMultidisciplinarybiologyVaccinationUncertaintyIMMUNIZATION3142 Public health care science environmental and occupational healthCOVERAGE3. Good healthTIME3.4 VaccinesChild PreschoolInfectious diseasesA990 Medicine and Dentistry not elsewhere classifiedAntibodyEngineering sciences. TechnologyAFRICAGeneral Science & TechnologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease prevention ; COVID-19 ; Public health ; Infectious diseases610 Medicine & healthGlobal Vaccine Action Plan (GVAP)Local Burden of Disease Vaccine Coverage CollaboratorsArticleVaccine Related03 medical and health sciencesmeasles vaccineMeasels ; Vaccination ; Low- and middle-income countries ; Local burden of disease ; Public healthClinical ResearchmedicineHumansHealthcare DisparitiesPreschoolPROGRESS030304 developmental biologybusiness.industryMORTALITYDeveloped CountriesPreventionCommentVacunaciónUrban HealthCOVID-19Prevention of disease and conditionsVirologyCoronavirusGood Health and Well BeingCobertura de Vacunaciónbiology.proteinImmunizationbusinessMeasles
researchProduct

T cell specificity and cross reactivity towards enterobacteria,Bacteroides,Bifidobacterium, and antigens from resident intestinal flora in humans

1999

BACKGROUNDT cell responses to normal intestinal bacteria or their products may be important in the immunopathogenesis of chronic enterocolitis.AIMSTo investigate the T cell specificity and cross reactivity towards intestinal bacteria.PATIENTS/METHODST cell clones were isolated with phytohaemagglutinin from peripheral blood and biopsy specimens of inflamed and non-inflamed colon from five patients with inflammatory bowel disease (IBD) and two controls. T cell clones were restimulated with anaerobicBacteroides andBifidobacteria species, enterobacteria, and direct isolates of aerobic intestinal flora. T cell phenotype was analysed by single-cell immunocyte assay.RESULTSAnalysis of 96 T cell cl…

biologyT cellGastroenterologybiology.organism_classificationmedicine.disease_causeCross-reactivityMicrobiologymedicine.anatomical_structureImmune systemAntigenImmunologymedicinebiology.proteinAnaerobic bacteriaBacteroidesBifidobacteriumPhytohaemagglutininGut
researchProduct

The spectrum of allergic (cross-)sensitivity in clinical patch testing with 'para amino' compounds

2002

Background: Allergic contact sensitization to ‘para amino’ compounds is frequent and the spectrum of cross-reactivity between members of this chemical group is variable. Methods: A retrospective analysis of clinical patch test data obtained with a special test series in the centres of the Information Network of Departments of Dermatology (IVDK) between 1995 and 1999. Results: In the 638 patients tested with the above test panel positive reactions were observed most often to p-aminoazobenzene (16.2%), p-phenylenediamine (14.1%), p-toluylenediamine (10.0%), followed by 4,4′-diaminodiphenylmethane (8.5%), Disperse Orange 3 (8.4%) and p-aminophenol (3.1%). Among the 544 patients tested with p-p…

medicine.medical_specialtyAllergyConcordanceCross sensitivityStatistics as TopicImmunologyCross ReactionsPhenylenediaminesAminophenolsmedicine.disease_causeCross-reactivity030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compoundSulfanilamide0302 clinical medicineGermanySulfanilamidesmedicineHumansImmunology and AllergyAminesRetrospective Studiesbusiness.industryPatch testp-PhenylenediamineAllergensPatch Testsmedicine.diseaseDermatology3. Good healthchemistryP-Aminoazobenzenep-Aminoazobenzene030220 oncology & carcinogenesisDermatitis Allergic ContactImmunologybusiness4-Aminobenzoic AcidContact dermatitisAllergy
researchProduct